Datta N R, Pasricha R, Gambhir S, Phadke R V, Prasad S N
Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Clin Oncol (R Coll Radiol). 2004 Oct;16(7):494-500. doi: 10.1016/j.clon.2004.06.021.
To evaluate if postoperative residual tumour imaged by either computed tomography or 201Tl single photon emission tomography (SPECT) carried out postoperatively could predict progression-free survival (PFS) in high-grade malignant gliomas.
Thirty-three patients with high-grade malignant gliomas underwent both contrast-enhanced CT scan and 201Tl-SPECT postoperatively before receiving radiotherapy. The PFS was evaluated against the individual reports of the above two imaging studies by univariate analysis.
CT and 201Tl-SPECT were carried out within a median interval of 17 days after surgery. Of the 33 patients, CT and 201Tl-SPECT were reported as positive for residual tumours in 23 (69.7%) and 30 (91%) patients, respectively. Sensitivity, specificity and overall accuracy were 71.4%, 40% and 66.6% for CT, and 96.4%, 40% and 87.8% for 201Tl-SPECT, respectively, and were based on their last follow-up status (P = 0.627 for CT; P = 0.053 for 201Tl-SPECT). The median PFS for patients reported to be positive or negative on CT scan was 4 and 5 months, respectively (P = 0.202). With 201Tl-SPECT, although the median PFS for patients with a positive 201Tl uptake was also 4 months, it had not even reached for those reported having a negative 201Tl uptake (cumulative survival 66.7% at last follow-up) (P = 0.198). However, Karnofsky performance status (KPS) was the only significant predictor on univariate analysis (KPS: < 80 vs. > or = 80; P < 0.001) for PFS.
Although both the imaging modalities have a poor specificity, postoperative 201Tl-SPECT had a significantly better accuracy to predict the status at last follow-up than contrast-enhanced CT. Nevertheless, KPS remained the most significant outcome predictor for PFS in high-grade malignant gliomas.
评估术后通过计算机断层扫描(CT)或术后进行的201铊单光子发射断层扫描(SPECT)所显示的残留肿瘤是否能够预测高级别恶性胶质瘤的无进展生存期(PFS)。
33例高级别恶性胶质瘤患者在接受放疗前术后均接受了增强CT扫描和201Tl-SPECT检查。通过单因素分析根据上述两项影像学检查的个体报告评估无进展生存期。
CT和201Tl-SPECT在术后中位间隔17天内进行。33例患者中,CT和201Tl-SPECT报告残留肿瘤阳性的分别为23例(69.7%)和30例(91%)。基于其末次随访状态,CT的敏感性、特异性和总体准确率分别为71.4%、40%和66.6%,201Tl-SPECT分别为96.4%、40%和87.8%(CT的P = 0.627;201Tl-SPECT的P = 0.053)。CT扫描报告为阳性或阴性的患者中位无进展生存期分别为4个月和5个月(P = 0.202)。对于201Tl-SPECT,虽然201Tl摄取阳性患者的中位无进展生存期也是4个月,但201Tl摄取阴性患者的无进展生存期甚至尚未达到(末次随访时累积生存率66.7%)(P = 0.198)。然而,在单因素分析中卡诺夫斯基功能状态(KPS)是无进展生存期的唯一显著预测因素(KPS:< 80 vs.≥80;P < 0.001)。
虽然两种影像学检查的特异性都较差,但术后201Tl-SPECT在预测末次随访状态方面的准确性明显优于增强CT。尽管如此,KPS仍然是高级别恶性胶质瘤无进展生存期最重要的预后预测因素。